The C4C application integrates Novo Nordisk’s diabetes knowledge and personalized patient support with Glooko’s digital platform and data analytics, the companies said, and is the 1st jointly developed product from the pair, which announced a collaborative deal in January.
“More people than ever are using mobile apps for chronic disease management, and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data. By leveraging the expertise and capabilities of Glooko, combined with Cornerstones4Care content, we were able to build a truly unique app to better support people with diabetes. Ultimately our digital health solution will help health care practitioners gain round-the-clock insight into their patients, and empower people with diabetes to better manage their diabetes, with the aim of ultimately leading to better diabetes management outcomes,” Glooko CEO Rick Altinger said in a press release.
The application is designed to allow individuals with diabetes to measure and track blood glucose, activities and meals in a central location, and will serve as a framework for additional jointly-developed tools from the companies.
The companies said that the C4C app uses Glooko’s tech designed to sync a user’s blood glucose and activity data from “the majority of” currently available diabetes and exercise devices, and can identify trends to aid in understanding factors that impact blood glucose.
“For over 90 years, Novo Nordisk has continued to develop innovative diabetes medicines and devices. In today’s environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise. That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions and we are excited about our combined capabilities and what that can do for improving diabetes treatment,” Novo Nordisk senior VP David Moore said in a prepared statement.